3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
35
CNS
7
Breast
4
Thoracic
3
Sarcoma
3
Other
3
Genitourinary
3
Gastrointestinal
3
Lymphoid
2
Gynecologic
2
Endocrine
2
Dermatologic
2
Plasma cell
1
Other solid neoplasm
1
Other neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Conditions
Neuroendocrine Tumors
102
Carcinoid Tumor
22
Neoplasms
16
Neoplasm Metastasis
10
Gastro-enteropancreatic neuroendocrine tumor
10
Carcinoma, Neuroendocrine
9
Adenoma, Islet Cell
9
Pancreatic Neoplasms
7
Carcinoma
7
Pheochromocytoma
6
Paraganglioma
6
Neuroblastoma
6
Colorectal Neoplasms
6
Carcinoma, Islet Cell
6
Somatostatinoma
5
Gastrointestinal Neoplasms
5
Vipoma
4
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Neuroectodermal Tumors, Primitive
4
Melanoma
4
Medulloblastoma
4
Lung Neoplasms
4
Intestinal Neoplasms
4
Gastrinoma
4
Carcinoma, Non-Small-Cell Lung
4
Adenocarcinoma
4
Prostatic Neoplasms
3
Neuroectodermal Tumors
3
Neoplasms, Nerve Tissue
3
Interventions
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Salivary Gland Neoplasms
×
NET
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts